Acute and Chronic Pancreatitis
1. Kaiypov Abdumazhit
2. Akshay Rathod
Sahil Akare
Ishant Nimbalkar
(1. Teacher, Surgery Dept., International Medical Faculty, Osh State University, Osh, Kyrgyz Republic.
2. Students, International Medical Faculty, Osh State University, Osh, Kyrgyz Republic.)
Abstract
Pancreatitis is a group of inflammatory disorders of the pancreas that can range from an acute, self-limiting illness to a chronic, progressive fibroinflammatory disease with irreversible structural damage. The aim of this review is to collate the existing literature regarding the pathophysiology, diagnosis, and treatment of both acute and chronic pancreatitis. Acute pancreatitis is an illness that occurs in 34 cases per 100,000 people each year. Gallstones and alcohol are the most common causes. Though 80% of cases are mild, 30% of severe cases are fatal. Chronic pancreatitis is an irreversible fibroinflammatory disease of the pancreas with 50 cases per 100,000 people. Among these cases, 50% are caused by alcohol. The recent advances that have been made in the treatment of acute pancreatitis include the stratification of severity according to the Revised Atlanta Classification system. The best fluids to be used for resuscitation have also been clearly defined. The recent advances that have been made in the treatment of chronic pancreatitis include nanotechnology-based diagnostics and treatment options. The review also emphasizes the need for an individualized treatment approach for the patient with pancreatitis. The review also emphasizes the need for future research to be done regarding the treatment of pancreatitis.
1. Introduction
The pancreas is a retroperitoneal organ with both exocrine and endocrine functions. It is prone to inflammatory conditions ranging from acute to irreversible damage. Acute pancreatitis (AP) and chronic pancreatitis (CP) are two distinct but related conditions. Together, they pose a significant health problem worldwide.
Acute pancreatitis is an acute inflammatory process of the pancreas. It may be associated with the involvement of other tissues or remote organ systems. It is one of the most common gastrointestinal diseases requiring hospitalization. Its incidence ranges from 13 to 45 per 100,000 population annually. Severe acute pancreatitis still carries a high morbidity and mortality rate despite advances in diagnostic modalities. This leads to a significant economic burden on the health care system.
Chronic pancreatitis is a progressive fibroinflammatory condition that results in irreversible changes in the pancreas, such as atrophy, fibrosis, calcifications, and ductal abnormalities. The changes in the pancreas result in a progressive impairment in both exocrine and endocrine pancreatic functions. The impairment in exocrine and endocrine pancreatic functions results in malabsorption, malnutrition, and pancreatogenic diabetes. The condition also results in a reduction in quality of life and an increased risk of pancreatic ductal adenocarcinoma. The relationship between AP and CP is complex and bidirectional. Recurrent episodes of acute pancreatitis have been identified as a significant risk factor for the development of chronic pancreatitis. The probability of developing chronic pancreatitis increases from 16% after the first episode to 50% after the third or fourth episode. The observation supports the hypothesis that an initial episode of acute pancreatitis sensitize the pancreas to subsequent injuries that result in chronic inflammation and fibrosis. Significant progress has been achieved in the last few years in the pathogenesis of pancreatitis, diagnostic criteria, and management strategies. For instance, the publication of new guidelines on the management of AP by the International Association of Pancreatology 2025 guidelines for AP and CP by a mechanistic definition provides clinicians with a framework for the management of these conditions. In addition, the development of new technologies like nanotechnology provides a promising direction for the management of the limitations that exist in the management of AP and CP.
The aim of this comprehensive review is to provide a synthesis of the current knowledge on AP and CP, particularly on the pathophysiology, management strategies, and emerging therapies for these conditions. This review provides clinicians and researchers with a comprehensive overview of AP and CP by examining these conditions from the perspectives of new guideline recommendations and emerging therapies.
2. Methods
The present narrative review was carried out by systematically searching the PubMed/MEDLINE, Embase, and Cochrane Library databases for literature published between January 2015 and February 2026. The literature search used a combination of the following keywords: "acute pancreatitis," "chronic pancreatitis," "diagnosis," "management," "guidelines," "nanotechnology," "complications," etc. Emphasis was given to randomized controlled trials, meta-analyses, systematic reviews, and clinical practice guidelines. Additional literature was also searched by manually perusing the reference lists of key papers. The selection criteria included the following: (1) publication in English; (2) human subjects; (3) a sample size of at least 20 subjects for original research; and (4) publication within the last ten years unless the work was historical or seminal. In addition, the quality of the evidence was assessed based on criteria that have been previously described.
3. Results
3.1 Acute Pancreatitis
3.1.1 Definition and Diagnostic Criteria
Acute pancreatitis is defined as an acute inflammatory process in the pancreas that occurs by different inflammatory mechanisms due to a number of causes . For diagnosis, any two out of three criteria must be present: (1) clinical presentation compatible with AP (acute onset of persistent, severe epigastric pain often radiating to the back); (2) lipase or amylase levels at least three times normal; and (3) characteristic features on CECT, MRI, or transabdominal ultrasonography.
The 2025 International Association of Pancreatology guidelines for the diagnosis of AP reaffirm the previous criteria for diagnosis while emphasizing that lipase levels are preferred over amylase levels for diagnosis due to their increased sensitivity and longer half-life . Transabdominal ultrasonography is recommended for imaging in AP due to the provision of useful information not only for diagnosis but also for etiological diagnosis, especially for gallstones. CECT or MRI may be used if the diagnosis is uncertain on ultrasonography for further evaluation.
3.1.2 Etiology
The etiology of AP is varied and includes gallstones and alcohol consumption in 70-80% of cases . Gallstones induce pancreatitis by either transient or permanent obstruction of the ampulla of Vater by stones. The obstruction causes hypertension in the pancreatic duct and premature activation of digestive enzymes in the pancreatic parenchyma. On the other hand, alcohol-induced pancreatitis is associated with several mechanisms that include the toxic effects of alcohol on acinar cells, sensitization to calcium signaling disruption, and increased protein secretion that causes the formation of a thick pancreatic fluid
Other causes of pancreatitis include hypertriglyceridemia, where serum triglycerides exceed 1000 mg/dL; endoscopic retrograde cholangiopancreatography-induced pancreatitis; drugs such as azathioprine, valproic acid, and diuretics; trauma; infections such as mumps and Coxsackie virus; and genetic mutations. The 2025 IAP guidelines highlight the need for identifying the etiology of pancreatitis since this determines the recurrence and preventive measures.
3.1.3 Pathophysiology
The pathogenesis of AP starts with the premature activation of digestive enzymes, which are activated within the pancreas, with the main enzyme being trypsinogen, which becomes activated to form the autodigestive enzyme known as trypsin. This, in turn, results in the autodigestion of the pancreas, leading to the release of damage-associated molecular patterns, which activate the resident macrophages within the pancreas, as well as the recruitment of leukocytes. This inflammatory response results in the release of pro-inflammatory cytokines, which include IL-1, IL-6, and TNF-a, which can result in the production of systemic inflammatory response syndrome (SIRS).
Recent studies have shown the pathogenesis of AP due to the impaired calcium signaling mechanism. The effect of alcohol and its metabolites on the cell's ability to respond to calcium signaling results in the impairment of the cell's ability to respond to the signal, leading to cell damage, which results in cell death.
The severity of AP is regulated by the balance between pro-inflammatory and anti-inflammatory responses. Excessive pro-inflammatory responses are responsible for early organ dysfunction, whereas anti-inflammatory responses may contribute to the development of infectious complications. This dual pattern of mortality from SIRS/multi-organ dysfunction early in the course and infected necrosis later in the course represents the complex immunological mechanisms in AP.
3.1.4 Severity Classification and Risk Stratification
The Revised Atlanta Classification, supported by gastroenterology and pancreatology professional societies, classifies the severity of AP into three distinct grades according to the presence of organ failure and local or systemic complications:
Mild Acute Pancreatitis: No organ failure. No local or systemic complications. Self-limiting. Recovery occurs within the first week. This type accounts for 80% of all AP
Moderately Severe Acute Pancreatitis: Transient organ failure resolving within 48 hours. Transient local or systemic complications without organ failure. Good outcome. Specialized care may be needed.
Severe Acute Pancreatitis: Persistent organ failure (»48 hours) involving one or more organ systems. Single or multiple organ failure. Mortality rate approaches 30%.
Several scoring systems are available for early risk stratification. The Bedside Index for Severity in Acute Pancreatitis (BISAP) scoring system, which includes blood urea nitrogen, altered mental status, SIRS, age, and pleural effusion, is recommended for routine clinical practice due to its simplicity and its ability to be comparable to other complex scoring systems . Blood urea nitrogen and elevated levels of creatinine during the first 48 hours are independently associated with increased mortality and morbidity . An increase in C-reactive protein levels of more than 150 mg/L during the first 48 hours is a reliable indicator of poor prognosis
3.1.5 Initial Management Fluid Resuscitation
Fluid resuscitation is considered the cornerstone of initial AP treatment. The goal is to correct hypovolemia while ensuring sufficient pancreatic microcirculation. Crystalloids are the fluids of choice for resuscitation. Normal saline is not the best choice; however, balanced fluids are increasingly favored over normal saline.
A recent systematic review and meta-analysis of balanced fluids (lactated Ringer's solution, acetate Ringer's solution) compared to normal saline solution for AP treatment found clinical benefits for balanced fluids. Compared to normal saline solution, balanced fluids reduced the risk of progressing to moderately severe or severe AP (odds ratio 0.50; 95% confidence interval 0.29 to 0.85), reduced the risk of requiring intensive care unit admission (odds ratio 0.60; 95% confidence interval 0.39 to 0.93), and reduced hospital length of stay (mean difference -0.88 days; 95% confidence interval -1.48 to -0.28). Balanced fluids are preferred for AP treatment; however, lactated Ringer's solution is preferred for AP treatment unless contraindications such as hypercalcemia are present.
The rate of fluid resuscitation should be tailored according to the characteristics of the patients. More importantly, aggressive fluid resuscitation, particularly in patients with moderate to severe AP and severe AP, is not recommended as it may result in SIRS, organ failure, the need for intensive care unit admission, and abdominal compartment syndrome. The fluid resuscitation should be tailored according to the clinical parameters such as heart rate, mean arterial pressure, central venous pressure, and urine output.
Adequate pain relief is also important for the management of AP. Non-steroidal anti-inflammatory agents such as indomethacin, metamizole, dexketoprofen, and diclofenac have shown to have the same efficacy as opioids for pain relief in the first 24 hours of mild AP. The advantage of using NSAIDs is that they do not have the side effects of opioids like sedation, respiratory depression, or gastrointestinal hypomotility. However, they are not to be used in patients with renal failure or those who are prone to renal failure.
Nutritional Support
Nutritional support in the early stages has experienced a paradigm shift in recent times. Oral feeding should not be withheld unless contraindicated by intestinal obstruction, ileus, and abdominal compartment syndrome. Early oral feeding, when tolerated, maintains the barrier function of the gut, reduces infections, and shortens the hospital stay.
Unless oral feeding can be started within 72 hours, nutritional support should be started . Enteral nutrition should be given preference over parenteral nutrition due to better outcomes in terms of reduced infections, mortality rates, and hospitalization days. The method by which enteral nutrition can be given is through a nasogastric tube and a nasojejunal tube. Both tubes have shown comparable results in terms of safety and efficacy.
For those who are not able to tolerate EN, for whom tube placement is not possible, or for whom nutritional needs cannot be met with EN alone, PN should be provided. The supplementation of glutamine to nutritional formulas is advised for those who need nutritional support based on the demonstration of improved outcomes.
Antibiotic Use
The routine use of antibiotics is not advised for AP, including severe cases of pancreatitis or those with necrosis. This is based on consistent evidence from randomized trials and meta-analyses showing no benefit for the prevention of infected necrosis or reduction of mortality rates but possible harm from antibiotic resistance and side effects.
The routine use of antibiotics is advised for cases of infected necrosis or extrapancreatic infections. Prompt antibiotic therapy is advised for those whose infections are suspected based on clinical deterioration, gas within necrotic collections seen on imaging, or positive cultures.
In a recent randomized controlled trial, where oral rifaximin was used in preventing infected pancreatic necrosis in patients with predicted severe AP, no significant decrease in infected necrosis incidence (31% vs 35%, p=0.507) and mortality (9% vs 14%, p=0.603) was observed However, rifaximin-treated patients had a shorter hospital stay compared with controls (8 days vs 11.5 days, p=0.002), implying a potential positive effect on recovery, which should be further explored
3.2 Chronic Pancreatitis
3.2.1 Definition and Diagnostic Framework
Chronic pancreatitis is a fibroinflammatory condition that is characterized by irreversible changes in the pancreatic structure and function. In 2016, the international societies of the pancreas introduced a mechanistic definition of chronic pancreatitis that defined the end-stage of chronic pancreatitis as including pancreatic atrophy, fibrosis, pain syndromes, duct distortion or stricture, calcifications, exocrine dysfunction, endocrine dysfunction, and dysplasia. The definition also addresses the mechanism of the disease as a pathological fibroinflammatory process occurring in an individual who has genetic, environmental, or other risk factors resulting in a pathologic response to injury or stress to the pancreas.
The mechanistic definition of chronic pancreatitis acknowledges that chronic pancreatitis is not an irreversible process but is a dynamic process that progresses through stages. The stages of chronic pancreatitis include: (1) at risk (asymptomatic before first pancreatic injury); (2) acute pancreatitis or recurrent acute pancreatitis; (3) early chronic pancreatitis (with detectable biomarkers but potentially reversible or irreversible); and (4) established chronic pancreatitis to end-stage chronic pancreatitis.
3.2.2 Etiology and Risk Factors
According to the TIGAR-O system, the six categories of the etiology of CP are as follows: Toxic-metabolic, Idiopathic, Genetic, Autoimmune, Recurrent severe acute pancreatitis, and Obstructive.
Alcohol consumption is the most common cause of CP, accounting for 50% of the cases in the US . Alcohol causes an increase in the secretion of protein from acinar cells, leading to more viscous fluid, which results in ductal obstruction, acinar cell fibrosis, and atrophy. However, only less than 10% of individuals with alcohol use disorder develop CP, which implies that other factors, including genetic factors, contribute to the disease, as seen with the effect of smoking, which increases the risk of CP, both as a single agent and with alcohol. The genetic causes are being recognized increasingly, especially among younger patients without the usual risk factors. Mutations of the genes PRSS1, SPINK1, CFTR, and CTRC have been implicated in causing pancreatitis. These genes encode the proteins cationic trypsinogen, pancreatic secretory trypsin inhibitor, cystic fibrosis transmembrane conductance regulator, and chymotrypsin C. The mutations may cause pancreatitis by increasing the activation of trypsin, decreasing the inhibition of trypsin, or by causing a defect in the ductal secretion of bicarbonate. SPlNK1-related CP histopathologically resembles alcoholic CP. PRSS1-related CP shows progressive lipomatous atrophy.
Autoimmune pancreatitis is a distinct form of pancreatitis that can be treated with corticosteroids. Obstructive causes of pancreatitis are pancreatic ductal strictures, tumors, and pancreas divisum.
3.2.3 Epidemiology
The exact epidemiology of CP is difficult to determine due to the difficulties in diagnosis and the delay in the onset of the disease. An epidemiological report from 2014 indicated that the incidence of the disease was stable, with the prevalence possibly underestimated. The prevalence of CP is higher in blacks than in whites in the US. The risk factors differ between the sexes, with alcohol and tobacco being the major factors for men, while idiopathic and obstructive factors are common in women Overall, the prevalence of the disease is higher in men than women, possibly due to the higher prevalence of alcohol and tobacco use. The age at diagnosis is approximately 45 years, with a later age of onset in the Asian population.
3.2.4 Pathophysiology and Disease Progression
The pathogenesis of CP is the result of complex interactions between genetic factors and environmental influences. There are two theories that explain the pathogenesis of the disease:
According to the first theory, the lack of counterbalance of the increase of protein secretion from the pancreas due to impaired secretion of bicarbonate results in the formation of plugs within the lobules and ducts, causing calcification and stone formation. The second theory involves the intraparenchymal activation of digestive enzymes due to genetic factors or environmental influences, such as alcohol consumption.
The pathogenic effects of alcohol consumption on the pancreas result from impaired cellular responses to calcium signaling, which sets the stage for a cycle of cell damage leading to cell death. This results in the progressive fibrosis of the pancreas, with activated pancreatic stellate cells producing extracellular matrix, which replaces the normal tissue.
Recurrent acute pancreatitis episodes significantly increase CP risk. Continued alcohol consumption contributes to progressive damage, and each recurrent episode causes further injury to an already compromised pancreas. By the third episode and beyond, acute pancreatitis tends to be more severe than initial occurrences, and affected individuals often exhibit clinical, biochemical, and imaging findings consistent with CP
The key pathological features include immune dysfunction resulting in fibrosis, dysfunction of the acinar cells resulting in exocrine dysfunction, dysfunction of the islet cells resulting in pancreatogenic diabetes (type 3c), pain resulting in chronic pain syndrome, and metaplasia resulting in pancreatic ductal adenocarcinoma.
3.2.5 Clinical Presentation
The clinical presentation of chronic pancreatitis is usually a history of pain that has lasted for a prolonged period. The pain is usually episodic and may be absent for a period. The pain may be less when the individual leans forward. The pain may be constant in the later stages. Accompanying the pain may be nausea, vomiting, and appetite loss.
The exocrine dysfunction presents clinically when there is a loss of over 90% of the pancreatic function. This occurs at least five years after the onset of the disease. The clinical features include steatorrhea or fatty stools that are difficult to flush, azotorrhea or foul-smelling stools due to maldigestion of proteins, weight loss, and fat-soluble vitamin deficiency including vitamin A, vitamin D, vitamin E, and vitamin K. Endocrine dysfunction causes pancreatogenic diabetes or type 3c diabetes. The condition is distinct from type 1 or 2 diabetes based on differences in the pathophysiology and treatment. Glucagon deficiency increases the risk of hypoglycemia.
The physical examination may reveal abdominal pain or tenderness, which can be localized or diffuse. A palpable mass may be indicative of a pseudocyst. The presence of malnutrition signs such as muscle wasting, loss of subcutaneous fat, cheilosis, and glossitis is also possible.
3.2.6. Diagnostic Evaluation
The mechanistic definition of CP combines clinical features, risk factors, and biomarkers. The diagnostic evaluation starts with a detailed history that involves pain pattern, steatorrhea, weight loss, alcohol consumption, tobacco habits, family history, and previous episodes of acute pancreatitis.
The laboratory tests include serum amylase, lipase, glucose levels, IgG4 for autoimmune pancreatitis, and triglycerides. Nutritional status is checked by measuring fat-soluble vitamin levels. Fecal eIastase-1 levels from a random stool sample are a useful tool for assessing exocrine pancreatic function. Normal levels are »500 pg/g; borderline levels are between 200-500 pg/g; moderate insufficiency is between 100-200 pg/g; and severe insufficiency is <100 pg/g. Though fecal eIastase-1 is less sensitive than the 72-hour quantitative fecal fat test for diagnosing steatorrhea, which is the definitive test for widely used.
Imaging is central in the diagnosis of CP. Computed tomography (CT) and magnetic resonance cholangiopancreatography (MRCP) are first-choice imaging modalities that can identify calcifications ("hallmark" sign), pancreatic enlargement or atrophy, ductal dilation or stricture, and complications such as pseudocysts.
Endoscopic ultrasound (EUS) is useful in early CP before fibrosis occurs, allowing detection of parenchymal and ductal abnormalities with high sensitivity. EUS is, however, invasive, not very specific, and is used when other imaging modalities are normal or unavailable. The Rosemont criteria are used for EUS-based diagnosis of CP based on parenchymal abnormalities (hyperechoic foci, stranding, lobularity, cysts) and duct abnormalities (main duct dilation, irregularity, hyperechoic margins, calculi, side branch dilation).
Endoscopic retrograde cholangiopancreatography (ERCP) is not used for CP diagnosis but is employed therapeutically for ductal structures and stones.
3.2.7 Complications
Pancreatic pseudocysts are a complication that occurs in a proportion of individuals, due to the disruption of the ducts, leading to the accumulation of pancreatic fluid. Pseudocysts can cause pain, gastric outlet obstruction, biliary obstruction, or infection. The presence of blood within the pseudocysts can lead to a serious complication of life-threatening proportions.
Bile duct strictures are due to the presence of fibrosis within the head of the pancreas, leading to obstructive jaundice, which can cause cholangitis. There can also be duodenal obstruction due to the inflammatory mass or pseudocyst.
Vascular complications can arise due to splenic vein thrombosis, leading to left-sided portal hypertension with gastric varices, the formation of pseudoaneurysms, which can occur from the gastroduodenal artery or splenic pancreatic ductal adenocarcinoma risk is significantly increased in CP, with cumulative risk approximately 4% over 20 years. Any unexplained symptom worsening or new stricture warrants investigation for malignancy.
3.2.8 Management Strategies Lifestyle Modifications
All patients with CP should abstain from alcohol and tobacco, regardless of etiology. Smoking cessation reduces pain, slows disease progression, and decreases pancreatic cancer risk. Alcohol cessation prevents ongoing parenchymal injury and may reduce pain episodes. Pain Management The management of pain is the most difficult part in the management of CP. The use of a multimodal method for pain management is effective in controlling both nociceptive and neuropathic pain. Low-fat meals taken 4-5 times a day help in reducing pancreatic stimulation and pain. The use of a combination of non-opioid analgesics such as acetaminophen and NSAIDs is the first choice in the management of pain. Adjuvants such as antidepressants for neuropathic pain, such as tricyclic antidepressants, gabapentin, pregabalin, and selective serotonin reuptake inhibitors, can be given in combination with analgesics. The use of opioids in pain management is associated with the risk of addiction. The use of opioids in the management of pain should be carefully monitored and a treatment agreement should be obtained. The use of endoscopic techniques in the management of pain in patients with CP is effective. The use of ERCP and sphincterotomy relieves pain in patients. ESWL can be used for the fragmentation of large stones in the pancreatic duct. The use of ESWL makes the stones easier to remove. The use of endoscopic techniques in the management of pseudo.
Surgical intervention is considered when the outcome of endoscopic treatment is unsatisfactory or not feasible. When the pancreatic duct is dilated (»7mm), a procedure called lateral pancreaticojejunostomy (Puestow procedure) is performed to create a conduit. This procedure relieves pain in 70 to 80 percent of patients. When the inflammatory mass is located in the pancreatic head and the duct is not dilated, pancreaticoduodenectomy (Whipple procedure) or duodenum-preserving pancreatic head resection (Beger or Frey procedure) is performed to remove the diseased pancreatic tissue. Early surgical intervention (<3 years since onset of symptoms) is more effective in eliminating or minimizing the degree of pain and slowing the surgery
Pancreatic Enzyme Replacement Therapy
Pancreatic enzyme replacement therapy (PERT) is used to treat pancreatic exocrine insufficiency. The enteric-coated microsphere formulation taken with meals increases fat and protein absorption, reduces steatorrhea, increases weight gain, and improves quality of life. The dose is tailored to the amount of fat consumed and the patient's response. Acid suppression with proton pump inhibitors or H2 receptor antagonists is used as an adjunct to prevent degradation of the enzymes by gastric acids.
Diabetes Management
Pancreatogenic diabetes (Type 3c) is a form of diabetes that requires careful management. The use of oral hypoglycemic agents is not recommended, as they are ineffective. The use of insulin is recommended, but the lack of glucagon increases the risk of hypoglycemia, which requires careful management of insulin doses, glucose levels, and patient education on the management of hypoglycemia.
Nutritional Support
Assessment and intervention for nutritional support are important. Fat-soluble vitamins, including Vitamins A, D, E, and It are essential for the correction of deficiencies. Medium-chain triglyceride is used as a source of energy, which is not dependent on the action of pancreatic lipase.
3.3 Emerging Therapeutic Strategies
3.3.1 Nanotechnology in Acute Pancreatitis
Nanotechnology is a paradigm shift in the diagnosis and treatment of AP, as current clinical approaches are limited in their ability to detect and target AP with adequate sensitivity and specificity, which are provided by nano-reagents.
In diagnosis, nano-sensor technology, both optical and electrochemical, as well as MRI, are useful in early detection of biomarkers and imaging of lesions in pancreatitis, which may detect AP earlier than current approaches and possibly differentiate grades of severity before clinical decompensation occurs. In treatment, nano-reagents are useful in overcoming challenges in treating AP, which include overcoming the blood-pancreatic barrier, specificity of drugs, and intervention in pathogenesis, as follows:
Multi-faceted approaches include targeted delivery systems for drug concentration at sites of inflammation, microenvironmental trigger systems for drug release in response to pH and enzymatic activity, and biological modulation of inflammation and cell death pathway regulation through precisely delivered molecular inhibitors.
The theranostic nano-reagents that combine diagnosis and therapy have shown promise for the simultaneous diagnosis of the severity of AP and the effectiveness of targeted therapy based on the ongoing activity of the nanosensors.
Although further optimization is needed for clinical application for AP management in terms of biocompatibility and validation, nanotechnology has the potential to revolutionize the management of AP by improving diagnosis, targeted therapy, and individualized treatment algorithms.
3.3.2 Advances in Interventional Management
With recent advances in interventional radiology/endoscopy procedures, the treatment options for complications of CP have increased. Endoscopic ultrasound-guided drainage procedures have replaced surgical procedures like cystogastrostomy for the treatment of pseudocysts. Similarly, vascular complications are also treated by interventional radiology procedures like coil embolization for pseudoaneurysms.
The idea of managing patients with complex cases of CP by a multidisciplinary team of surgeons/endoscopists/ interventional radiologists has become the norm. This ensures that treatment options are tailored to each patient based on their specific condition.
4. Discussion
The management of pancreatitis, both as a disease concept and as a practical intervention, has undergone a significant evolution over the last several decades. However, challenges still exist, as shall be seen in the following review, which synthesizes the current state of knowledge, as well as areas of knowledge deficit and research priorities for the future.
4.1 Integrating Acute and Chronic Pancreatitis Concepts
The traditional concept of AP and CP as two separate diseases has now been replaced by the concept of the relationship between the two diseases. The transition from recurrent acute pancreatitis to chronic pancreatitis, as shown by epidemiological studies and as a component of the pathogenetic definition of CP, supports the concept of the disease continuum. This concept is of practical significance, as the prevention of AP can lead to the prevention of CP. The factors that determine which patient with AP progresses to CP are a critical research priority.
4.2 Evidence-Based Management: Progress and Controversies
Recent guideline changes offer better evidence for some aspects of management. The updated 2025 IAP guidelines and Turkish consensus report offer detailed recommendations based on systematic evidence reviews. The reliance on balanced approaches in fluid resuscitation, validated by meta-analyses showing improved outcomes, is a major step forward in clinical management.
Some issues remain contentious, including fluid resuscitation rate, where evidence supports that under- and over-resuscitation are both harmful. Individualized resuscitation based on dynamic parameters may be optimal but lacks validated algorithms. The benefit of new antibiotic regimens, including rifampicin, reducing hospital stay without affecting infected necrosis or mortality, needs clarification of its mechanism of action and patient group that would benefit.
Pain management in CP is particularly difficult. The ineffectiveness of existing regimens and opioid-related problems highlight an urgent need for effective analgesics that target pancreatitis pain pathways. The improved outcomes of early surgical management challenge traditional step-up approaches and suggest that earlier referral to specialists for consideration of definitive procedures is required.
4.3 Emerging Technologies: Promise and Prerequisites
Nanotechnology-based applications for AP represent one of the most promising emerging fields. The ability to achieve early diagnosis via ultrasensitive biomarker detection, target therapy to treat AP via the blood-pancreatic barrier, and theranostic agents that combine monitoring and treatment capabilities holds great promise to revolutionize the treatment of AP. However, many challenges need to be addressed before nanotechnology can be successfully translated to the clinic. These challenges include optimizing biocompatibility, scalability, regulatory approvals, and clinical efficacy and cost-effectiveness. Progress from the preclinical stage to clinical implementation is an effort that needs to be made by all those who are basic scientists, translational researchers, and clinicians.
Similarly, improvements in interventional treatments for CP, including enhanced endoscopic techniques and endovascular therapy, have increased the treatment options for CP but need to be compared to surgical treatments to determine the best approach for patient selection and treatment timing.
4.4 Clinical Implications
For clinicians dealing with pancreatitis, several key principles can be derived from the current evidence. First, early risk stratification in AP using a validated scoring system can help in the allocation of resources appropriately. Second, fluid resuscitation with balanced fluids at individually tailored rates is a key factor that can influence the outcome. Third, nutritional support should focus on early initiation of oral or enteral feeding rather than fasting. Fourth, antibiotics should be avoided and reserved for specific infections only.
For the management of CP, a holistic approach that includes pain relief, exocrine and endocrine deficiencies, nutritional status, and complications requires coordination. Early consideration of endoscopic and surgical interventions in suitable candidates can influence long-term outcomes. Lifestyle modifications for all patients should focus on alcohol and tobacco cessation.
4.5 Research Priorities
This review also points out several priority areas that need future research focus. In AP, effective therapeutic agents that control systemic inflammation and organ dysfunction are needed. The reason why some patients develop severe disease, whereas others make a full recovery, could be determined, which could reveal therapeutic targets and enable personalized medicine approaches.
For CP, understanding the mechanism of progression of fibrosis could reveal therapeutic targets for its prevention or treatment. More effective pain control measures that address central sensitization and changes in the peripheral nerves, which are seen in CP, are needed. The timing of endoscopic versus surgical approaches could be determined through comparative effectiveness studies, including long-term outcomes. Prevention of this disease in high-risk groups, including hereditary pancreatitis, is also an area that needs to be investigated.
5. Conclusion
Acute and chronic pancreatitis encompass a group of inflammatory conditions affecting the pancreas that cause a high burden of morbidity and mortality. While acute pancreatitis is mild and self-limiting in 80% of patients, its mortality rate is as high as 30% in severe cases. The main causes of acute pancreatitis remain gallstones and alcohol consumption. Genetic factors and hypertriglyceridemia have also emerged as important causes. The evidence-based recommendations for acute pancreatitis include early risk stratification, fluid resuscitation with balanced solutions, and avoiding antibiotics. The Revised Atlanta Classification is useful for severity assessment and guiding clinical management and research. Chronic pancreatitis is a progressive fibroinflammatory condition that causes permanent damage to the pancreas. The mechanistic definition of chronic pancreatitis by international consensus statements recognizes different stages in the development and progression of chronic pancreatitis. The main cause in adults remains alcohol consumption. Genetic factors have also emerged as an important cause in younger individuals. The management of chronic pancreatitis includes the management of the pain, exocrine and endocrine pancreatic insufficiency. The management is multimodal and includes lifestyle modifications, pharmacotherapy, endoscopy, and surgery. Pain management in chronic pancreatitis remains the biggest challenge.
The relationship between acute and chronic pancreatitis, with the progression of recurrent acute pancreatitis to chronic pancreatitis, underscores the potential for preventing the disease. The identification of factors that influence the progression from acute to chronic pancreatitis could help in the identification of therapeutic targets as well as the population that could benefit from aggressive monitoring and treatment strategies.
In terms of new technologies that could help alleviate the current shortcomings in the early detection and treatment of pancreatitis, nanotechnology-based diagnostic and therapeutic strategies hold significant promise. Although significant validation is required for these technologies to be implemented for the treatment of pancreatitis, they could hold the key to a new era in the management of pancreatitis.
In terms of the management of pancreatitis, it is evident that a multifaceted approach is required to address the complex interplay of factors that contribute to the development of pancreatitis. As the understanding of the mechanisms of pancreatitis increases and new therapeutic strategies are developed, the prognosis for patients with these debilitating conditions continues to look bright.
References
Banks PA, Bollen TL, Dervenis C, Gooszen HG, Johnson CD, Sarr MG, et al. Classification of acute pancreatitis—2012: Revision of the Atlanta classification and definitions by international consensus. Gut. 2013;62(1):102—111.
Boxhoorn L, Voermans RP, Bouwense SA, Bruno MJ, Verdonk RC, Boermeester MA, et al. Acute pancreatitis. Lancet. 2020;396(10252):726—734.
Forsmark CE, Vege SS, Wilcox CM. Acute pancreatitis. New England Journal of Medicine. 2016;375(20):1972—1981.
Whitcomb DC. Genetic risk factors for pancreatic disorders. Gastroenterology. 2013;144(6):1292—1302.
Yadav D, Lowenfels AB. The epidemiology of pancreatitis and pancreatic cancer. Gastroenterology. 2013;144(6):1252—1261.
Mederos MA, Reber HA, Girgis MD. Acute pancreatitis: A review. JAMA. 2021;325(4):382—390.
Crockett SD, Wani S, Gardner TB, Falck-Ytter Y, Barkun AN. American Gastroenterological Association Institute guideline on initial management of acute pancreatitis. Gastroenterology. 201B;154(4):1096—1101.
B. Gardner TB, Adler DG, Forsmark CE, Sauer BG, Taylor JR, Whitcomb DC. ACG clinical guideline: Chronic pancreatitis. American Journal of Gastroenterology. 2020;115(3):322—339.
Lévy P, Dominguez-Muñoz E, lmrie C, Lohr M, Maisonneuve P. Epidemiology of chronic pancreatitis. Best Practice & Research Clinical Gastroenterology. 2010;24(3):337—350.
Petrov MS, Yadav D. Global epidemiology and holistic prevention of pancreatitis. Nature Reviews Gastroenterology & Hepatology. 2019;16(3):175—184.
Witt H, Apte MV, Keim V, Wilson JS. Chronic pancreatitis: Challenges and advances in pathogenesis, genetics, diagnosis, and therapy. Gastroenterology. 2007;132(4):1557—1573.
Drewes AM, Bouwense SA, Campbell CM, Ceyhan GO, Delhaye M, Demir IE, et al. Guidelines for the understanding and management of pain in chronic pancreatitis. Pancreatology. 2017;17(5):720—731.
Tenner S, Baillie J, DeWitt J, Vege SS. American College of Gastroenterology guideline: Management of acute pancreatitis. American Journal of Gastroenterology. 2013;108(9):1400—1415.
Singh VK, Yadav D, Garg PK. Diagnosis and management of chronic pancreatitis: A review. JAMA. 2019;322(24):2422—2434.
Banks PA, Freeman ML. Practice guidelines in acute pancreatitis. American Journal of Gastroenterology. 2006;101(10):2379—2400.